Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation - PubMed (original) (raw)
Clinical Trial
. 2001 Feb 1;97(3):631-7.
doi: 10.1182/blood.v97.3.631.
P F Thall, I Khouri, X Wang, I Braunschweig, C Ippolitti, D Claxton, M Donato, J Bruton, A Cohen, M Davis, B S Andersson, P Anderlini, J Gajewski, S Kornblau, M Andreeff, D Przepiorka, N T Ueno, J Molldrem, R Champlin
Affiliations
- PMID: 11157478
- DOI: 10.1182/blood.v97.3.631
Free article
Clinical Trial
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
S Giralt et al. Blood. 2001.
Free article
Abstract
A reduced-intensity preparative regimen consisting of melphalan and a purine analog was evaluated for allogeneic transplantation in 86 patients who had a variety of hematologic malignancies and were considered poor candidates for conventional myeloablative therapies because of age or comorbidity. Seventy-eight patients received fludarabine 25 mg/m(2) daily for 5 days in combination with melphalan 180 mg/m(2) (n = 66) or 140 mg/m(2) (n = 12). Eight patients received cladribine 12 mg/m(2) continuous infusion for 5 days with melphalan 180 mg/m(2). The median age was 52 years (range, 22-70 years). Disease status at transplantation was either first remission or first chronic phase in 7 patients, untreated first relapse or subsequent remission in 16 patients, and refractory leukemia or transformed chronic myelogenous leukemia in 63 patients. Nonrelapse mortality rates on day 100 were 37.4% for the fludarabine/melphalan combination and 87.5% for the cladribine/melphalan combination. The median percentage of donor cells at 1 month in 75 patients was 100% (range, 0%-100%). The probability of grade 2-4 and 3-4 acute graft-versus-host disease was 0.49 (95% CI, 0.38-0.60) and 0.29 (95% CI, 0.18-0.41), respectively. Disease-free survival at 1 year was 57% for patients in first remission or chronic phase and 49% for patients with untreated first relapse or in a second or later remission. On multivariate analysis the strongest predictor for disease-free survival was a good or intermediate risk category. In summary, fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population.
Similar articles
- Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Slack JL, et al. Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7. Biol Blood Marrow Transplant. 2013. PMID: 23664940 - A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. Shore T, et al. Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006. Biol Blood Marrow Transplant. 2006. PMID: 16864057 Clinical Trial. - Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K. Devine SM, et al. Bone Marrow Transplant. 2001 Sep;28(6):557-62. doi: 10.1038/sj.bmt.1703198. Bone Marrow Transplant. 2001. PMID: 11607768 Clinical Trial. - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review. - Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.
Shenoi J, Gopal AK, Press OW, Pagel JM. Shenoi J, et al. Curr Opin Oncol. 2010 Mar;22(2):143-9. doi: 10.1097/CCO.0b013e328335ccc2. Curr Opin Oncol. 2010. PMID: 20019612 Review.
Cited by
- Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.
Esquirol A, Cadenas IG, Novelli S, Garrido A, Caballero AC, Oñate G, Lopez J, Redondo S, Argüello M, Saavedra S, Moreno C, Briones J, Sierra J, Martino R. Esquirol A, et al. Ann Hematol. 2024 Jan;103(1):321-334. doi: 10.1007/s00277-023-05530-w. Epub 2023 Nov 16. Ann Hematol. 2024. PMID: 37971549 - Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Chichra A, Nayak L, Kothari R, Kalantri S, Bonda A, Gokarn A, Punatar S, Mirgh S, Jindal N, Bagal B, Kannan S, Mathew L, Khattry N. Chichra A, et al. Int J Hematol. 2024 Jan;119(1):71-79. doi: 10.1007/s12185-023-03674-z. Epub 2023 Nov 12. Int J Hematol. 2024. PMID: 37952243 - Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.
Yanada M, Harada K, Shimomura Y, Arai Y, Konuma T. Yanada M, et al. Front Oncol. 2022 Nov 25;12:1050633. doi: 10.3389/fonc.2022.1050633. eCollection 2022. Front Oncol. 2022. PMID: 36505853 Free PMC article. Review. - Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.
Wong JYC, Liu A, Han C, Dandapani S, Schultheiss T, Palmer J, Yang D, Somlo G, Salhotra A, Hui S, Al Malki MM, Rosenthal J, Stein A. Wong JYC, et al. Front Oncol. 2022 Oct 3;12:1003908. doi: 10.3389/fonc.2022.1003908. eCollection 2022. Front Oncol. 2022. PMID: 36263219 Free PMC article. Review. - Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation.
Del Galy AS, Rousseau A, Capes A, Michonneau D, Robin M, de Fontbrune FS, Xhaard A, Frieri C, Adès L, Raffoux E, Himberlin C, Baudet M, Peffault de Latour R, Socié G. Del Galy AS, et al. Bone Marrow Transplant. 2022 Sep;57(9):1365-1372. doi: 10.1038/s41409-022-01715-5. Epub 2022 Jun 2. Bone Marrow Transplant. 2022. PMID: 35654824
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources